Super, please list 25 high profile medical device regulation updates by FDA, EU, NMPA, MFDS, ANvISA, HSA, TGA, PMDA, Health canada and UK in 2025 in a table with title. description, reference, comments
Below is a selected overview of 25 high‑profile medical device‑related regulatory updates across 10 jurisdictions in 2025, synthesized from major reforms, consultations, and guidance releases. These are not an exhaustive legal list but represent major, market‑shaping developments in each agency’s ecosystem during 2025.

2025 Medical Device Regulation Updates Table
Title	Jurisdiction	Description (brief)	Reference	Comments
FDA enforcement‑discretion phase‑out for LDTs	FDA (USA)	FDA begins phasing out enforcement‑discretion for lab‑developed tests (LDTs) through five stages over four years; from May 6, 2025 LDT manufacturers must comply with MDR, correction/removal reporting, and QS complaint‑file requirements. 
FDA “LDT Enforcement Discretion Final Rule” phases starting May 6, 2025. 
​	Major shift toward formal device‑like oversight of LDTs; increases QMS, vigilance, and registration load.
FDA‑finalized AI‑ML SaMD lifecycle guidance (Dec 2024/2025 rollout)	FDA (USA)	Guidance finalizes expectations on pre‑specified change‑control plans for AI/ML‑enabled SaMD, lifecycle‑management, and “model in production” monitoring. 
FDA draft guidance “AI‑Enabled Device Software Functions: Lifecycle Management” (Jan 6, 2025). 
​	Formalizes PCCP concept; aligns with IMDRF AI‑ML‑SaMD thinking. 
​
FDA‑issue‑specific guidance on AI in device development	FDA (USA)	2025 draft guidance clarifies use of AI to generate evidence or outputs for regulatory decisions, introducing a “credibility” framework and COU‑driven validation. 
​	FDA 2025 draft guidance on AI/ML in drug and device development. 
​	Positions AI‑support tools closer to regulated devices; stresses transparency and bias assessment.
FDA‑accelerated review concepts for AI/ML devices	FDA (USA)	Streamlining framework for modifications to AI/ML‑based SaMD adopted for devices in firmware/software changes, recognizing >950‑1,200 AI clearances. 
FDA “Proposed Regulatory Framework for Modifications to AI/ML‑Based SaMD” and firmware‑update guidance. 
​	Encourages iterative learning while retaining safety checks.
FDA‑updated GMLP‑style expectations for ML in devices	FDA (USA)	Builds on 2025 IMDRF Good ML Practice, highlighting 10 principles for quality data, model monitoring, and explainability. 
FDA‑referenced IMDRF “Good Machine Learning Practice” document (Jan 2025). 
​	Provides global‑baseline GMLP‑alignment for device‑grade ML.
EU‑MDR/IVDR targeted evaluation & simplification proposal	EU‑MDR & IVDR	Commission launches 2025‑targeted evaluation and proposes simplification of MDR/IVDR, including redesigned transition‑period‑style rules and de‑bureaucratization. 
EC legislative proposal “targeted simplification of MDR/IVDR” (Dec 16, 2025). 
​	Early‑signal package for future EU‑MDR‑2‑style reforms; focuses on timelines and data‑sharing.
EU‑EUDAMED four‑modules “fully functional” decision with 2026 mandates	EU‑MDR	Decision (EU) 2025/2371 confirms four MDR/IVDR modules (Actor, UDI/Device, NB/Certificates, Market Surveillance) are functional, triggering mandatory use from May 28, 2026. 
Commission Decision (EU) 2025/2371; EUDAMED MDR assessments. 
Major transparency milestone; all manufacturers must register SRNs and devices by 2026 deadlines.
EU‑legacy‑device transition‑extension rules for MDR/IVDR	EU‑MDR	Regulation (EU) 2024/1860‑driven changes tighten legacy‑device conditions (no equivalent CE product; stricter QMS) and extend some transition‑period‑type provisions. 
​	Regulation (EU) 2024/1860 underlying amendments. 
​	Increases scrutiny and burden on legacy fleets; effective Jan 2025.
EU‑mandatory real‑world evidence‑type reporting obligations	EU‑MDR	New information‑duty changes under 2024/1860 increase real‑world‑data–related reporting and follow‑up for high‑risk devices. 
​	MDR‑linked amendments and EUDAMED‑module requirements. 
Strengthens post‑market safety evidence‑generation expectations.
EU‑harm‑reduction focused review of harmonised standards	EU‑MDR	Implementing Decision (EU) 2026/193 updates harmonised standards (e.g., neuro‑surgical implants, biological/clinical evaluation, sterilisation, small‑bore connectors), guiding post‑2024 MDR‑related conformity. 
​	EU Commission Implementing Decision (EU) 2026/193. 
​	Harmonises technical compliance with latest ISO‑2023/2024‑style revisions.
NMPA‑2025 medical‑device industry standard plan with 85 standards	NMPA (China)	Announces 2025‑plan for 85 device‑industry standards (6 mandatory, 79 recommended), harmonizing with ISO in anesthesia, IVD, AI, and additive manufacturing. 
​	NMPA 2026‑04‑10 “2025 Medical Device Industry Standard Formulation and Revision Plan”. 
​	Tightens China‑specific technical baselines; must be met for registration and market access.
NMPA‑mandatory‑standard updates in high‑risk areas (anesthesia, oxygenators, etc.)	NMPA (China)	6 mandatory standards revised or drafted, including resuscitators (adopting ISO 10651‑4), oxygenators (ISO 7199:2024), balloon‑catheters (ISO 10555‑4), and thermally conductive therapy equipment. 
​	NMPA 2025 standard table (e.g., YY 0600.4‑2013 → ISO 10651‑4:2023, YY 1048‑2016 → ISO 7199:2024). 
​	Directly impacts high‑risk and long‑term‑implant‑type devices in China.
MFDS‑long‑term follow‑up requirement for implantable devices	MFDS (Korea)	From Jan 31, 2025, implantables must show long‑term follow‑up if they have ≥1 annual adverse‑event‑type report or risk of serious/fatal effects. 
​	MFDS Medical Devices Act amendments with effective date Jan 31, 2025. 
​	Raises PMS/PRS burden for implantables; similar risk‑proportionate‑logic in other markets.
MFDS‑amendments on RWD and sensitive‑data handling	MFDS (Korea)	Regulatory changes effective Aug 1, 2025 allow collection and analysis of real‑world data while defining rules for processing privacy‑sensitive information. 
​	MFDS subordinate regulations (Medical Devices Act and Regulations) amendments. 
​	Supports evidence‑generation but implies stricter data‑governance and privacy‑impact‑checking.
ANVISA‑2025 registration manual with “summary rejection” policy	ANVISA (Brazil)	2025 “Manual for Registration of Materials for Use in Health” introduces strict “zero‑tolerance” standards and summary‑rejection of incomplete dossiers under RDC 751/2022. 
​	ANVISA 2025 Registration Manual (Dec 2025 release). 
​	Increases dossier‑quality and completeness pressure; may shrink pipeline queues and speed compliant‑device entry.
HSA‑Singapore multi‑guidance package on compliance and grouping	HSA (Singapore)	Nov 5, 2025 guidance updates for medical‑device registration, compliance‑grouping rules, and submission processes to streamline review and enhance safety expectations. 
​	HSA guidance documents, Nov 2025. 
​	Aids in batch‑registration planning and simplifies multi‑device‑family‑compliance‑assessment.
TGA‑AI/Software‑based tool compliance update	TGA (Australia)	2025 compliance update clarifies that AI or software tools providing diagnostic or treatment suggestions fall under medical‑device‑regulation unless exempt (ARTG inclusion). 
​	TGA 2025 compliance update under Therapeutic Goods Act 1989. 
​	Broadens Australian watch‑list for “digital‑scribe”‑type tools and AI‑diagnostic products.
PMDA‑Japan pre‑market and reimbursement reforms	PMDA (Japan)	2025‑rated guidance describes tightened‑evidence requirements and updates to inspection‑fee‑linked reimbursement processes (PMD Act amendments). 
​	Pacific Bridge‑style MHLW/PMDA 2025‑regulatory‑landscape update. 
​	Dual‑emphasis on safety evidence and market‑access‑linked pricing pressure.
Health‑Canada‑classification‑and‑MDL‑clarity package	Health Canada	Industry‑oriented 2025‑materials clarify the role of MDEL vs. MDL, ISO 13485/MDSAP expectations, and timelines for Class II–IV device licences. 
​	Health Canada 2025‑medical‑device‑licensing overviews. 
​	Not a formal rule but de‑facto reference point for Canadian submissions and audits.
MHRA‑new UK post‑market surveillance regime (Part 4A MDR)	UK‑MHRA	From June 16, 2025, post‑market‑surveillance‑requirements amendments require risk‑proportionate PMS systems for CE/UKCA‑marked devices in GB. 
Medical Devices (Post‑market Surveillance Requirements) (Amendment) (GB) Regs 2024; SI 2024 No. 1368. 
​	Introduces tighter PMS‑design expectations ahead of full statutory‑reform wave.
MHRA‑roadmap‑linked reforms for pre‑market device‑regulation in GB	UK‑MHRA	Updated MDR‑roadmap through 2025 clarifies consultations and expected dates for new pre‑market rules (including international reliance and classification alignment). 
MHRA MDR Roadmap (rev. Dec 2024, implementing from 2025). 
​	Positions UK for more flexible, foreign‑mark‑based approvals and updated IVD‑classification logic.
MHRA‑announcement to adopt device UDI and implant‑cards requirement	UK‑MHRA	MHRA declares that new legislation will require UDI‑like identifiers on devices and implant‑cards for patients; up‑classification and UDI‑database prep commence in 2025. 
MHRA consultation‑response documents and roadmap (2024‑2025). 
Mirrors EU‑UDI logic; long‑term aim to phase‑out UKCA‑mark dependence where aligned with foreign‑marks.
MHRA‑new rules on digital mental‑health and AI‑driven tools	UK‑MHRA	2025‑planned amendments target software and AI‑driven digital‑mental‑health technologies, under revised Medical Device Regulations (2002). 
MHRA 2025–26 reform roadmap (public‑health “new regulations” page). 
​	Specific focus on real‑world‑use‑tracking and patient‑safety‑incident‑reporting for mental‑health‑apps.
MHRA‑consultation‑response on IVD classification shifts	UK‑MHRA	Response to 2024–25 IVD consultation flags alignment of GB‑IVD classes with IMDRF‑style risk groups and new pre‑market‑assessment tiers. 
MHRA consultation‑response documents (July 2025). 
​	Brings GB‑IVD scheme closer to global‑harmonization trends.
MHRA‑vision of relying on FDA, Health Canada & TGA approvals	UK‑MHRA	MHRA signals intent to allow reliance on devices already approved by FDA, Health Canada, and TGA to accelerate GB‑market access. 
MHRA regulatory‑reform and roadmap documents. 
​	Would reduce duplication of assessment if fully implemented through future regulations.
If you want, the next step can be:

a jurisdiction‑by‑jurisdiction deep‑dive (e.g., full‑list export‑style for FDA alone), or

a risk/impact‑scored view (high‑impact vs. medium‑impact changes) for your internal risk‑management or compliance‑roadmap.

Follow-ups

How do these 2025 updates impact global medtech compliance strategies

What are the compliance deadlines for FDA LDT regulations

Detailed steps for EU EUDAMED implementation in 2025

NMPA mandatory standards for AI diagnostics explained

TGA requirements for AI medical software tools in 2025
